洞察新型硫甲酸衍生物作为抗癌碳酸酶抑制剂
Rehab F Ahmed1, Walaa R Mahmoud2, Nagwa M Abdelgawad2
1Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt. rehab.abdelmoneim@pharma.cu.edu.eg.
Molecular diversity
|November 11, 2024
概括
合成了新的pyrazole衍生物,并测试了它们抑制与癌症相关的人类碳酸 anhydrase (hCA) 酶的能力. 有前途的化合物显示出显著的抗癌活性,并在癌细胞中诱导了亡,这需要进一步的研究.
科学领域:
- 药用化学 医学化学
- 生物化学 生化学
- 癌症研究 癌症研究
背景情况:
- 人类碳酸无水酶 (hCA) 与各种癌症有关.
- 向hCA异型是一种有前途的癌症治疗策略.
- 之前的研究已经探索了pyrazole衍生物的生物活性.
研究的目的:
- 为了合成和评估新型的pyrazole衍生物与硫甲基.
- 评估这些化合物对与癌症相关的hCA异型 (hCA IX和XII) 的抑制潜力.
- 为了研究最强效的化合物的抗癌疗效和作用机制.
主要方法:
- 合成可变的替代型pyrazoles.
- 在体外酶抑制对hCA IX和XII的测定.
- 在60个癌细胞系中查抗癌活性.
- 在MCF-7细胞上进行细胞周期分析和细胞亡测定.
- 分子建模模拟. 分子建模模拟.
主要成果:
- 化合物4e和6c对hCA IX和XII都表现出强烈的抑制作用.
- 化合物4a,5e和5b分别选择性抑制了hCA IX或hCA XII.
- 化合物4d和5a-d在多个细胞系中表现出显著的抗癌疗效.
- 化合物5b表现出强大的细胞毒性 (IC50 = 5.21 μM) 对MCF-7细胞和诱导的亡.
- 分子建模支持了体外发现.
结论:
- 新型pyrazole衍生物有效抑制与癌症相关的hCA异型.
- 选择的化合物显示出显著的抗癌性质,包括诱导亡.
- 这些发现突出了这些pyrazole衍生物在癌症治疗中的治疗潜力.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
226
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
226
Antihypertensive Drugs: Thiazide-Class Diuretics
546
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
546
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
148
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
148
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K


